Abstract
Lactoferrin, an iron-binding glycoprotein, is a cell-secreted mediator that bridges innate and adaptive immune function in mammals. It is a pleiotropic molecule that directly assists in the influence of presenting cells for the development of T-helper cell polarization. The aim of this review is to provide an overview of research regarding the role of lactoferrin in maintaining immune homeostasis, in particular as a mediator of immune responses to infectious assault, trauma and injury. These findings are critically relevant in the development of both prophylactic and therapeutic interventions in humans. Understanding these particular effects of lactoferrin will provide a logical framework for determining its role in health and disease.
Keywords: Lactoferrin, innate immunity, adaptive immunity, immunomodulation, inflammation, oxidative stress, adjuvant
Current Pharmaceutical Design
Title: Lactoferrin as a Natural Immune Modulator
Volume: 15 Issue: 17
Author(s): Jeffrey K. Actor, Shen-An Hwang and Marian L. Kruzel
Affiliation:
Keywords: Lactoferrin, innate immunity, adaptive immunity, immunomodulation, inflammation, oxidative stress, adjuvant
Abstract: Lactoferrin, an iron-binding glycoprotein, is a cell-secreted mediator that bridges innate and adaptive immune function in mammals. It is a pleiotropic molecule that directly assists in the influence of presenting cells for the development of T-helper cell polarization. The aim of this review is to provide an overview of research regarding the role of lactoferrin in maintaining immune homeostasis, in particular as a mediator of immune responses to infectious assault, trauma and injury. These findings are critically relevant in the development of both prophylactic and therapeutic interventions in humans. Understanding these particular effects of lactoferrin will provide a logical framework for determining its role in health and disease.
Export Options
About this article
Cite this article as:
Actor K. Jeffrey, Hwang Shen-An and Kruzel L. Marian, Lactoferrin as a Natural Immune Modulator, Current Pharmaceutical Design 2009; 15 (17) . https://dx.doi.org/10.2174/138161209788453202
DOI https://dx.doi.org/10.2174/138161209788453202 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Current Medicinal Chemistry Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment
Current Signal Transduction Therapy From the Sea to Anticancer Therapy
Current Medicinal Chemistry Editorial (Thematic Issue: Embryonic Signaling Pathways as Potential Targets for the Treatment of Rhabdomyosarcoma)
Current Drug Targets Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Current Pharmaceutical Biotechnology Comparative Genomic Hybridization: A Valuable Tool for Genome-Scale Analysis of Rodent Cancer Models
Current Genomics Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine GLUT4 Goes Abnormal: Disregulation of the Insulin-Responsive Glucose Transporter in Abnormal Metabolic States
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Nanosized Tamoxifen-Porphyrin-Glucose [TPG] Conjugate: Novel Selective Anti-breast-cancer Agent, Synthesis and In Vitro Evaluations
Medicinal Chemistry Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Fork Head Transcription Factors
Current Genomics Molecular Pathology of Sarcomas
Reviews on Recent Clinical Trials Urotensin-II Receptor Antagonists
Current Medicinal Chemistry Glycan-Binding Profile and Cell Adhesion Activity of American Bullfrog (Rana catesbeiana) Oocyte Galectin-1
Protein & Peptide Letters Targeting Apoptosis Resistance in Rhabdomyosarcoma
Current Cancer Drug Targets Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry